Servier increases its sales. The laboratory increased its revenue by 9.8% in the 2021-22 fiscal year compared to the previous year, up to 4,876 million euros. The company justifies this increase by the 7.6% rise in global sales volumes and a favorable exchange rate.
Oliver Laureau, President of Servier, explains that “in a complex and unstable geopolitical and economic environment, Servier has progressed in all business segments; The company is now a global healthcare player built around three balanced pillars, cardiometabolic and venous disease, oncology and generics.”
One part has been the complex situation of prices that have had a negative effect of 1% on revenue growth, an impact of 45 million euros. Despite this, international sales growth has increased. The proportion of income generated outside the European Union accounted for more than half of sales56%, which represents an increase from 1% to 6% of the previous fiscal year.
Servier had an operating result of 859 million euros in the fiscal year 2021-22
On the other hand, revenue from brand name drugs amounted to 3,694 million euros in the last fiscal year, 12.5%, more than the previous fiscal year. Sales revenue from the group’s generics business was flat compared to the constant exchange rates of the previous fiscal year and reached 1,182 million euros. Currently, Servier has more than 1,500 generic medicines that cover most of the pathologies that are distributed throughout the world.
The gross operating result (ebitda) of the company for the 2021-22 fiscal year amounted to 859 million euros, 34.6% more, and represented 17.6% of the group’s income, compared to 14% in the fiscal year former. Net profit also increased at 192 million euros compared to the 95 million euros they lost in the previous fiscal year.
Pascal Lemaire, Executive Vice President of Servier, highlights that “the strong growth in oncology sales and the significant investments made in recent years support Servier’s strategy to become a focused and innovative player in oncology, with the goal of achieving revenue of 3,000 million euros by 2030 in this area”.
Current annual results confirm the group’s trajectory to 2025 and its ability to achieve its targetssales revenue of €6 billion, including €1 billion in oncology, and an ebitda of €1.3 billion.
